Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This open-labeled, one-center study is designed to evaluate the efficacy and safety of
roxadustat in ESA-naïve and ESA-treated pediatric patients with CKD Stages 3, 4, and 5 who
are receiving dialysis or not. The study will enroll patients between the ages of 2 to <18
years. Approximately 30 patients will be enrolled.